Overview

Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Alefacept
Heptavalent Pneumococcal Conjugate Vaccine
Vaccines